Articles from Treatment.com AI Inc.

 

 

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) Announces Rocket Doctor’s Growth and Expansion in Alberta, Empowering Independent Physicians and Enhancing Patient Access to Care.

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) Announces Rocket Doctor’s Growth and Expansion in Alberta, Empowering Independent Physicians and Enhancing Patient Access to Care.

Vancouver, British Columbia, March 13, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce that further to its news releases dated February 27, 2025 and March 3, 2025, it has closed its previously announced brokered private placement under the Listed Issuer Financing Exemption (the “Offering”) with Ventum Capital Corp., (the “Underwriter”) who acted as underwriter pursuant to an underwriting agreement dated March 13, 2025 (the “Underwriting Agreement”).

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) Announces Rocket Doctor’s Approval as an In-Network Provider for New York Medicaid Strengthening Access to Virtual Healthcare Across the State and Collaboration with EngageWell.

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) Announces Rocket Doctor’s Approval as an In-Network Provider for New York Medicaid Strengthening Access to Virtual Healthcare Across the State and Collaboration with EngageWell.

●Treatment.com AI announces expanded and updated MES new releases

●Treatment.com AI announces expanded and updated MES new releases

Treatment.com AI CEO, Dr. Essam Hamza, is to present live at 11:00 AM ET on Wednesday, October 9, 2024.

Treatment.com AI CEO, Dr. Essam Hamza, is to present live at 11:00 AM ET on Wednesday, October 9, 2024.

VANCOUVER, British Columbia, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to provide marketing updates and a general corporate update on its focus on the utilization of AI within the medical education sector.

VANCOUVER, British Columbia, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to provide marketing updates and a general corporate update on its focus on the utilization of AI within the medical education sector.

VANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with SPRYT Limited (“SPRYT”). Both innovative AI healthcare organizations, SPRYT and Treatment are exploring complementary technology synergies, including Treatment’s proprietary Global Library of Medicine (“GLM”), to build new solutions designed to mitigate patient access challenges, administrative overheads for healthcare professionals and cost inefficiencies throughout our healthcare systems.

VANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with SPRYT Limited (“SPRYT”). Both innovative AI healthcare organizations, SPRYT and Treatment are exploring complementary technology synergies, including Treatment’s proprietary Global Library of Medicine (“GLM”), to build new solutions designed to mitigate patient access challenges, administrative overheads for healthcare professionals and cost inefficiencies throughout our healthcare systems.

VANCOUVER, British Columbia, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with the University Court of the University of Edinburgh (“University of Edinburgh”). The University of Edinburgh is looking to utilize Treatment’s proprietary Global Library of Medicine (“GLM”) to jointly build applications within the “SET4 Systems Engineering to Transform Transitions In Health and Social Care innovation initiative” (“SET4”).

VANCOUVER, British Columbia, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with the University Court of the University of Edinburgh (“University of Edinburgh”). The University of Edinburgh is looking to utilize Treatment’s proprietary Global Library of Medicine (“GLM”) to jointly build applications within the “SET4 Systems Engineering to Transform Transitions In Health and Social Care innovation initiative” (“SET4”).

VANCOUVER, British Columbia, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights, endorses the forward thinking emanating from a recent event in Washington comprising 25 of the nation’s leading experts on the appropriate use of artificial intelligence (AI) within healthcare.

VANCOUVER, British Columbia, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights, endorses the forward thinking emanating from a recent event in Washington comprising 25 of the nation’s leading experts on the appropriate use of artificial intelligence (AI) within healthcare.

VANCOUVER, British Columbia, July 31, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights is excited to announce a new solution, AI Pharmacy Assistant designed to support pharmacists. Pharmacists are playing an increasing role in the provision of clinical decision support services, given the increasing number of people without a GP and/or the time taken to book appointments.

VANCOUVER, British Columbia, July 31, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights is excited to announce a new solution, AI Pharmacy Assistant designed to support pharmacists. Pharmacists are playing an increasing role in the provision of clinical decision support services, given the increasing number of people without a GP and/or the time taken to book appointments.

●~800,000 warrants exercised since free trading was announced raising close to half a million dollars.

●~800,000 warrants exercised since free trading was announced raising close to half a million dollars.

●Positive Financial Update

●Positive Financial Update

VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with Health Care Services International Inc (o/a Novus Health). (“Novus Health”) to explore utilization of Treatment’s proprietary Global Library of Medicine (“GLM”) to further enhance Novus Health’s Health Risk Assessment programs.

VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights is pleased to announce the appointment of Richard Atkins as Chief Operating Officer and a member of the executive team.

VANCOUVER, British Columbia, May 01, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is excited to announce one of the leading US medical schools has agreed to a contract renewal utilizing Treatment’s Medical Education Suite (“MES”).

VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “ Company ” or “ Treatment ”) is excited to announce two new solutions, (1) AI Patient and (2) AI Doctor in a Pocket, to augment its Medical Education Suite (“ MES ”) designed to educate the next generation of healthcare providers.

VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “ Company ” or “ Treatment ”) is excited to announce two new solutions, (1) AI Patient and (2) AI Doctor in a Pocket, to augment its Medical Education Suite (“ MES ”) designed to educate the next generation of healthcare providers.

VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with aiXplain, Inc. (“aiXplain”) to enable greater access to Treatment’s proprietary Global Library of Medicine (“GLM”) by contributing to aiXplain’s ever-growing dynamic Artificial Intelligence (AI) marketplace.

VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) welcomes Prime Minister Justin Trudeau’s announcement on 7th April, 2024, that the federal government plans to fund $2.4 billion in its upcoming budget towards build capacity in Artificial Intelligence (AI) adoption.

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to announce that the Company has received funding from The National Institute of Health (“NIH”) to develop a culturally sensitive AI approach for collecting family medical history.

VANCOUVER, British Columbia, March 20, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to announce that it’s AI medical information support platform was used in the “Objective Structured Clinical Examination” (“OSCE”), a standard clinical exam of diagnostic aptitude at medical and nursing schools, passing the exam with a 92% success rate.

Vancouver, British Columbia, March 14, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce that, further to its news release dated February 16, 2024, it has closed a non-brokered private placement of 6,295,500 special warrants of the Company (each, a “Special Warrant”) at a price of $0.40 per Special Warrant, for aggregate gross proceeds of $2,518,200 and 975,000 units of the Company (each, a “Unit”) at a price of $0.40 per Unit, for aggregate gross proceeds of $390,000 (the “Offering”).

Vancouver, BC, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to announce the appointment of Mr. David Worner as Chief Financial Officer of the Company, effective February 5, 2024.